Wutah dodolan YoY sajrone 12 wulan kepungkur: Anixa Bio (ANIX)

Production optimization via CDMO plants eliminates equipment downtime for Anixa Biosciences, Inc. (ANIX). The annual revenue growth rate (rolling period) provided by the GURU.Markets platform demonstrates business adaptation, where 0.00 represents the current metric value. Success relies on the expertise of Amit Kumar's team and the development of cancer vaccines, the monetization of which is based on licensing fees and royalties.
Anixa - rincian analitis lan metrik utama (ANIX)

Strategic alliances of Anixa Biosciences, Inc. (ANIX) in the field of T-cell vaccine development drive its operating revenue dynamics. Analyzing the relative change in trailing twelve months (TTM) revenue compared to the same period last year allows for the removal of market noise, measuring the real TTM sales growth rate to assess the fundamental stability of the business and prevent overpaying for the asset during local peaks.